Department of Medicine, Harvard Medical School, Program in Nutritional Metabolism, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e.
Dyslipidemia is highly prevalent among patients living with chronic HIV infection and may confer increased risk of cardiovascular disease in this patient population. This review summarizes recent data investigating lipid abnormalities and its management in HIV-infected patients.
Studies in the last year have evaluated the effects of various lipid-lowering therapies not previously investigated in the HIV patient population. Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia.
Dyslipidemia is common in HIV-infected individuals. Medical therapy of lipid disorders needs to take potential drug-drug interactions of lipid-lowering medications and antiretroviral agents into consideration.
血脂异常在慢性 HIV 感染患者中非常普遍，可能会增加该患者人群患心血管疾病的风险。本综述总结了最近研究 HIV 感染患者中脂质异常及其管理的相关数据。
过去一年的研究评估了各种降脂治疗药物的作用，这些药物以前并未在 HIV 患者人群中进行过研究。瑞舒伐他汀是一种强效他汀类药物，似乎在患有高胆固醇血症的 HIV 感染患者中耐受性良好且有效。
血脂异常在 HIV 感染者中很常见。治疗血脂异常的药物治疗需要考虑降脂药物和抗逆转录病毒药物之间潜在的药物相互作用。
